Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors

Vitaly Margulis, Christopher G. Wood, Eric Jonasch, Surena F. Matin

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Cytoreductive nephrectomy (CN) has an established role against metastatic renal cell carcinoma (mRCC) in properly selected patients and offers a survival advantage when performed prior to cytokine therapy. With the emergence of new, effective targeted molecular therapies for mRCC, well-designed prospective trials are needed to clarify the biologic effects of CN to determine when and for whom CN should be performed in the context of targeted systemic therapy. Consequently, a thorough characterization of the systemic effects afforded by CN is imperative for developing individualized treatment strategies that effectively address the underlying biology of mRCC while maximizing patient quality of life during therapy. Until then, debulking surgery, which provides a survival benefit for select patients with mRCC, should continue to be used in patients before or after targeted systemic therapy.

Original languageEnglish (US)
Pages (from-to)253-258
Number of pages6
JournalCurrent Oncology Reports
Volume10
Issue number3
DOIs
StatePublished - 2008

Fingerprint

Nephrectomy
Protein-Tyrosine Kinases
Renal Cell Carcinoma
Molecular Targeted Therapy
Therapeutics
Survival
Quality of Life
Cytokines

ASJC Scopus subject areas

  • Oncology

Cite this

Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors. / Margulis, Vitaly; Wood, Christopher G.; Jonasch, Eric; Matin, Surena F.

In: Current Oncology Reports, Vol. 10, No. 3, 2008, p. 253-258.

Research output: Contribution to journalArticle

Margulis, Vitaly ; Wood, Christopher G. ; Jonasch, Eric ; Matin, Surena F. / Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors. In: Current Oncology Reports. 2008 ; Vol. 10, No. 3. pp. 253-258.
@article{e0df608264374a93b6053b81ef1d187e,
title = "Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors",
abstract = "Cytoreductive nephrectomy (CN) has an established role against metastatic renal cell carcinoma (mRCC) in properly selected patients and offers a survival advantage when performed prior to cytokine therapy. With the emergence of new, effective targeted molecular therapies for mRCC, well-designed prospective trials are needed to clarify the biologic effects of CN to determine when and for whom CN should be performed in the context of targeted systemic therapy. Consequently, a thorough characterization of the systemic effects afforded by CN is imperative for developing individualized treatment strategies that effectively address the underlying biology of mRCC while maximizing patient quality of life during therapy. Until then, debulking surgery, which provides a survival benefit for select patients with mRCC, should continue to be used in patients before or after targeted systemic therapy.",
author = "Vitaly Margulis and Wood, {Christopher G.} and Eric Jonasch and Matin, {Surena F.}",
year = "2008",
doi = "10.1007/s11912-008-0038-3",
language = "English (US)",
volume = "10",
pages = "253--258",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "3",

}

TY - JOUR

T1 - Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors

AU - Margulis, Vitaly

AU - Wood, Christopher G.

AU - Jonasch, Eric

AU - Matin, Surena F.

PY - 2008

Y1 - 2008

N2 - Cytoreductive nephrectomy (CN) has an established role against metastatic renal cell carcinoma (mRCC) in properly selected patients and offers a survival advantage when performed prior to cytokine therapy. With the emergence of new, effective targeted molecular therapies for mRCC, well-designed prospective trials are needed to clarify the biologic effects of CN to determine when and for whom CN should be performed in the context of targeted systemic therapy. Consequently, a thorough characterization of the systemic effects afforded by CN is imperative for developing individualized treatment strategies that effectively address the underlying biology of mRCC while maximizing patient quality of life during therapy. Until then, debulking surgery, which provides a survival benefit for select patients with mRCC, should continue to be used in patients before or after targeted systemic therapy.

AB - Cytoreductive nephrectomy (CN) has an established role against metastatic renal cell carcinoma (mRCC) in properly selected patients and offers a survival advantage when performed prior to cytokine therapy. With the emergence of new, effective targeted molecular therapies for mRCC, well-designed prospective trials are needed to clarify the biologic effects of CN to determine when and for whom CN should be performed in the context of targeted systemic therapy. Consequently, a thorough characterization of the systemic effects afforded by CN is imperative for developing individualized treatment strategies that effectively address the underlying biology of mRCC while maximizing patient quality of life during therapy. Until then, debulking surgery, which provides a survival benefit for select patients with mRCC, should continue to be used in patients before or after targeted systemic therapy.

UR - http://www.scopus.com/inward/record.url?scp=58149132465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149132465&partnerID=8YFLogxK

U2 - 10.1007/s11912-008-0038-3

DO - 10.1007/s11912-008-0038-3

M3 - Article

VL - 10

SP - 253

EP - 258

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 3

ER -